We have located links that may give you full text access.
THE ACUTE EFFECTS OF CANNABIS WITH AND WITHOUT CANNABIDIOL IN ADULTS AND ADOLESCENTS: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER EXPERIMENT.
Addiction 2023 Februrary 8
BACKGROUND AND AIMS: Long-term harms of cannabis may be exacerbated in adolescence, but little is known about the acute effects of cannabis in adolescents. We aimed to: (1) compare the acute effects of cannabis in adolescent and adult cannabis users, and (2) determine if cannabidiol (CBD) acutely modulates the effects of delta-9-tetrahydocannabinol (THC).
DESIGN: Randomised, double-blind, placebo-controlled, crossover experiment. The experiment was registered on ClinicalTrials.gov (NCT04851392).
SETTING: Laboratory in London, United Kingdom.
PARTICIPANTS: Twenty-four adolescents (12 women, 16-17 year-olds) and 24 adults (12 women, 26-29 year-olds) who used cannabis 0.5-3 days/week and were matched on cannabis use frequency (mean=1.5 days/week).
INTERVENTION: We administered three weight-adjusted vaporised cannabis flower preparations: 'THC' (8mg THC for 75kg person); 'THC+CBD' (8mg THC and 24mg CBD for 75kg person); and 'PLA' (matched placebo).
MEASUREMENTS: Primary outcomes were: i) subjective 'feel drug effect'; (ii) verbal episodic memory (delayed prose recall); and (iii) psychotomimetic effect (Psychotomimetic States Inventory).
FINDINGS: Compared with 'PLA', 'THC' and 'THC+CBD' significantly (p<0.001) increased 'feel drug effect' (mean difference (MD)=6.3, 95% confidence interval (CI) 5.3 to 7.2; MD=6.8, 95% CI 6.0 to 7.7), impaired verbal memory (MD=-2.7, 95% CI -4.1 to -1.4; MD=-2.9, 95% CI -4.1 to -1.7), and increased psychotomimetic effects (MD=7.8, 95% CI 2.8 to 12.7; MD=10.8, 95% CI 6.2 to 15.4). There was no evidence that adolescents differed from adults in their responses to cannabis (interaction p≥0.4). Bayesian analyses supported equivalent effects of cannabis in adolescents and adults (BF01 >3). There was no evidence that CBD significantly modulated the acute effects of THC.
CONCLUSIONS: Adolescent cannabis users are neither more resilient nor more vulnerable than adult cannabis users to the acute psychotomimetic, memory-impairing, or subjective effects of cannabis. Furthermore, in adolescents and adults, vaporised cannabidiol does not mitigate the acute harms caused by delta-9-tetrahydocannabinol.
DESIGN: Randomised, double-blind, placebo-controlled, crossover experiment. The experiment was registered on ClinicalTrials.gov (NCT04851392).
SETTING: Laboratory in London, United Kingdom.
PARTICIPANTS: Twenty-four adolescents (12 women, 16-17 year-olds) and 24 adults (12 women, 26-29 year-olds) who used cannabis 0.5-3 days/week and were matched on cannabis use frequency (mean=1.5 days/week).
INTERVENTION: We administered three weight-adjusted vaporised cannabis flower preparations: 'THC' (8mg THC for 75kg person); 'THC+CBD' (8mg THC and 24mg CBD for 75kg person); and 'PLA' (matched placebo).
MEASUREMENTS: Primary outcomes were: i) subjective 'feel drug effect'; (ii) verbal episodic memory (delayed prose recall); and (iii) psychotomimetic effect (Psychotomimetic States Inventory).
FINDINGS: Compared with 'PLA', 'THC' and 'THC+CBD' significantly (p<0.001) increased 'feel drug effect' (mean difference (MD)=6.3, 95% confidence interval (CI) 5.3 to 7.2; MD=6.8, 95% CI 6.0 to 7.7), impaired verbal memory (MD=-2.7, 95% CI -4.1 to -1.4; MD=-2.9, 95% CI -4.1 to -1.7), and increased psychotomimetic effects (MD=7.8, 95% CI 2.8 to 12.7; MD=10.8, 95% CI 6.2 to 15.4). There was no evidence that adolescents differed from adults in their responses to cannabis (interaction p≥0.4). Bayesian analyses supported equivalent effects of cannabis in adolescents and adults (BF01 >3). There was no evidence that CBD significantly modulated the acute effects of THC.
CONCLUSIONS: Adolescent cannabis users are neither more resilient nor more vulnerable than adult cannabis users to the acute psychotomimetic, memory-impairing, or subjective effects of cannabis. Furthermore, in adolescents and adults, vaporised cannabidiol does not mitigate the acute harms caused by delta-9-tetrahydocannabinol.
Full text links
Related Resources
Trending Papers
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app